Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up - Should You Buy?

Nuvectis Pharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

Error: Response status code does not indicate success: 500 (Internal Server Error).

Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report)'s share price gapped up prior to trading on Thursday. The stock had previously closed at $19.20, but opened at $20.48. Nuvectis Pharma shares last traded at $20.2750, with a volume of 7,363 shares traded.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on NVCT shares. Wall Street Zen downgraded Nuvectis Pharma from a "hold" rating to a "sell" rating in a research report on Saturday, November 7th. Loop Capital set a $40.00 target price on Nuvectis Pharma in a research report on Tuesday, September 1st. Lucid Cap Mkts upgraded Nuvectis Pharma to a "strong-buy" rating in a research report on Tuesday, September 1st. HC Wainwright restated a "buy" rating and issued a $39.00 target price on shares of Nuvectis Pharma in a research note on Thursday, September 24th. Finally, Zacks Research cut Nuvectis Pharma from a "hold" rating to a "strong sell" rating in a report on Thursday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $36.25.

View Our Latest Stock Analysis on Nuvectis Pharma

Nuvectis Pharma Stock Down 1.7%

The firm has a market capitalization of $685.72 million, a P/E ratio of -10.55 and a beta of -0.21. The firm's 50-day simple moving average is $20.36 and its 200-day simple moving average is $15.35.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($1.02) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.78). As a group, analysts expect that Nuvectis Pharma, Inc. will post -1.89 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc purchased a new stake in Nuvectis Pharma during the second quarter valued at about $31,000. Bank of America Corp DE purchased a new position in shares of Nuvectis Pharma in the 2nd quarter worth about $218,000. Avalon Trust Co purchased a new position in shares of Nuvectis Pharma in the 2nd quarter worth about $257,000. Deutsche Bank AG purchased a new position in shares of Nuvectis Pharma in the 2nd quarter worth about $310,000. Finally, Goldman Sachs Group Inc. increased its position in shares of Nuvectis Pharma by 67.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 34,372 shares of the company's stock valued at $726,000 after purchasing an additional 13,892 shares during the last quarter. 96.77% of the stock is currently owned by hedge funds and other institutional investors.

Nuvectis Pharma Company Profile

(Get Free Report)

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with serious diseases, particularly cancer. Its research and development programs target molecular pathways that may be relevant to specific tumor types. The company's pipeline includes NXP800, an investigational small-molecule drug designed to inhibit the heat shock factor 1 pathway, and NXP900, an investigational inhibitor of the SRC and YES1 kinases. Nuvectis has studied NXP800 in ovarian cancer and is developing NXP900 for solid tumors; both remain investigational and are not approved medicines.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Nuvectis Pharma Right Now?

Before you consider Nuvectis Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvectis Pharma wasn't on the list.

While Nuvectis Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines